Akiko Hata

Akiko Hata

Auto-generated profile, based on publicly available information

Akiko Hata

Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2008 in Nature
Verified
Journal Article
Closed access
PDF file
BDBrandi N. Davis
Brandi N. Davis
AHAaron C. Hilyard
Aaron C. Hilyard
GLGiorgio Lagna
Giorgio Lagna
AHAkiko Hata
Akiko Hata

1 August 2010 in Molecular Cell
Verified
Journal Article
Closed access
BDBrandi N. Davis
Brandi N. Davis
AHAaron C. Hilyard
Aaron C. Hilyard
PNPeter H. Nguyen
Peter H. Nguyen
GLGiorgio Lagna
Giorgio Lagna
AHAkiko Hata
Akiko Hata

10 August 2009 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
BDBrandi N Davis
Brandi N Davis
AHAkiko Hata
Akiko Hata
MicroRNAs are small, non-coding RNAs that influence diverse biological functions through the repression of target genes during normal development and pathological responses. Widespread use of microRNA arrays to profile microRNA expression has indicated that the levels of many microRNAs are altered during development and disease. These findings have prompted a great deal of investigation into the mechanism and function of microRNA-mediated repression. However, the mechanisms which govern the regulation of microRNA biogenesis and activity are just beginning to be uncovered. Following transcription, mature microRNA are generated through a series of coordinated processing events mediated by large protein complexes. It is increasingly clear that microRNA biogenesis does not proceed in a 'one-size-fits-all' manner. Rather, individual classes of microRNAs are differentially regulated through the association of regulatory factors with the core microRNA biogenesis machinery. Here, we review the regulation of microRNA biogenesis and activity, with particular focus on mechanisms of post-transcriptional control. Further understanding of the regulation of microRNA biogenesis and activity will undoubtedly provide important insights into normal development as well as pathological conditions such as cardiovascular disease and cancer.

1 February 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BDBrandi N. Davis
Brandi N. Davis
AHAaron C. Hilyard
Aaron C. Hilyard
PNPeter H. Nguyen
Peter H. Nguyen
GLGiorgio Lagna
Giorgio Lagna
AHAkiko Hata
Akiko Hata
The platelet-derived growth factor (PDGF) signaling pathway is a critical regulator of animal development and homeostasis. Activation of the PDGF pathway leads to neointimal proliferative responses to artery injury; it promotes a switch of vascular smooth muscle cells (vSMC) to a less contractile phenotype by inhibiting the SMC-specific gene expression and increasing the rate of proliferation and migration. The molecular mechanism for these pleiotropic effects of PDGFs has not been fully described. Here, we identify the microRNA-221 (miR-221), a small noncoding RNA, as a modulator of the phenotypic change of vSMCs in response to PDGF signaling. We demonstrate that miR-221 is transcriptionally induced upon PDGF treatment in primary vSMCs, leading to down-regulation of the targets c-Kit and p27Kip1. Down-regulation of p27Kip1 by miR-221 is critical for PDGF-mediated induction of cell proliferation. Additionally, decreased c-Kit causes inhibition of SMC-specific contractile gene transcription by reducing the expression of Myocardin (Myocd), a potent SMC-specific nuclear coactivator. Our study demonstrates that PDGF signaling, by modulating the expression of miR-221, regulates two critical determinants of the vSMC phenotype; they are SMC gene expression and cell proliferation.

1 November 2010 in Genes & Cancer
Verified
Journal Article
Closed access
BDB. N. Davis-Dusenbery
B. N. Davis-Dusenbery
AHA. Hata
A. Hata
MicroRNAs (miRNAs) are small, noncoding RNAs that influence diverse biological outcomes through the repression of target genes during normal development and pathological responses. In particular, the alteration of miRNA expression has dramatic consequences for the progression of tumorigenesis. miRNAs undergo two processing steps that transform a long primary transcript into the mature miRNA. Although the general miRNA biogenesis pathway is well established, it is clear that not all miRNAs are created equally. Recent studies show that miRNA expression is controlled by diverse mechanisms in response to cellular stimuli. In this review, we discuss the mechanisms that govern the regulation of miRNA biogenesis with particular focus on how these mechanisms are perturbed in cancer.

9 September 2010 in The Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
BDB. N. Davis
B. N. Davis
AHAkiko Hata
Akiko Hata
MicroRNAs (miRNAs) are a class of ∼22 nt non-coding RNAs that control diverse biological functions in animals, plants and unicellular eukaryotes by promoting degradation or inhibition of translation of target mRNAs. miRNA expression is often tissue specific and developmentally regulated. Aberrant expression of miRNAs has been linked to developmental abnormalities and human diseases, including cancer and cardiovascular disorders. The recent identification of mechanisms of miRNA biogenesis regulation uncovers that various factors or growth factor signalling pathways control every step of the miRNA biogenesis pathway. Here, we review the mechanisms that control the regulation of miRNA biogenesis discovered in human cells. Further understanding of the mechanisms that control of miRNA biogenesis may allow the development of tools to modulate the expression of specific miRNAs, which is crucial for the development of novel therapies for human disorders derived from aberrant expression of miRNAs.